Showing 7131-7140 of 9327 results for "".
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinomahttps://practicaldermatology.com/news/immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma/2459909/First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topa
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov
- Alastin Skincare's Latest Product May Become Body Contouring Procedures' New BFFhttps://practicaldermatology.com/news/alastin-skincares-latest-product-may-be-body-contouring-procedures-new-bff/2457573/
- Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 for Chemotherapy-Associated Paronychiahttps://practicaldermatology.com/news/veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-for-chemotherapy-associated-paronychia/2457580/Veloce BioPharma, LLC, a clinical-stage biopharmaceutical company dedicated to developing topical therapeutics for unmet needs in dermatologic and ophthalmic diseases, shared positive results of its Phase 2b study of dilute povidone-iodine in a novel DMSO solvent system for the topical treatment
- FDA Green Lights First Spray-on-Skin Product for Burnshttps://practicaldermatology.com/news/fda-green-lights-first-spray-on-skin-product-for-burns/2457598/The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The U.S. market launch for the Recell Autologous Cell Harvesting Device (RECELL® System) is
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- Demand for Vegan Cosmetics Expected to Soarhttps://practicaldermatology.com/news/demand-for-vegan-cosmetics-to-soar-bi-2025/2457631/The global vegan cosmetics market size is projected to reach $20.8 billion by 2025, progressing at a Compound Annual Growth Rate (CAGR) of 6.3 percent during the forecast period. Spiraling demand for vegan cosmetics among millennials is one of the primary growth stimulants of the market,
- Report: Psoriasis in America in 2018https://practicaldermatology.com/news/report-psoriasis-in-america-in-2018/2457640/Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms—and the mental emotional effects of those symptoms—are overwhelming. The survey, "
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o